´ç´¢È²¹ÝºÎÁ¾¿¡¼ ¾È³» º£¹Ù½ÃÁÖ¸¿ Ä¡·á ÈÄ ºû°£¼·´ÜÃþÃÔ¿µÀ» ÀÌ¿ëÇÑ ¸Á¸· Ç÷°ü Á÷°æÀÇ º¯È
Retinal Vascular Caliber Changes on OCT after Intravitreal Bevacizumab Injection in Diabetic Macular Edema
±è¿µÁØ, ±èÇüÀº, ¼Û¿ø°æ, ±è¼º¼ö,
¼Ò¼Ó »ó¼¼Á¤º¸
±è¿µÁØ ( Kim Young-Jun ) - ¿¬¼¼´ëÇб³ Àǰú´ëÇÐ ¾È°úÇб³½Ç
±èÇüÀº ( Kim Hyoung-Eun ) - ¿¬¼¼´ëÇб³ Àǰú´ëÇÐ ¾È°úÇб³½Ç
¼Û¿ø°æ ( Song Won-Kyung ) - Æ÷õÁß¹®Àǰú´ëÇб³ ºÐ´çÂ÷º´¿ø ¾È°úÇб³½Ç
±è¼º¼ö ( Kim Sung-Soo ) - ¿¬¼¼´ëÇб³ Àǰú´ëÇÐ ¾È°úÇб³½Ç
KMID : 0360220120530020262
Abstract
¸ñ Àû: ºû°£¼·´ÜÃþÃÔ¿µ(OCT)À» ÀÌ¿ëÇÏ¿© ´ç´¢È²¹ÝºÎÁ¾ ȯÀÚ¿¡¼ ¾È³» º£¹Ù½ÃÁÖ¸¿(Bevacizumab) ÁÖ»ç ÈÄ ¸Á¸· Ç÷°ü Á÷°æÀÇ º¯È¸¦ ¾Ë¾Æº¸¾Ò´Ù.
´ë»ó°ú ¹æ¹ý: ´ç´¢È²¹ÝºÎÁ¾À¸·Î 1.25 mg/0.05 ml ¾È³» º£¹Ù½ÃÁÖ¸¿ Áֻ縦 ¹ÞÀº ȯÀÚ 29¸í, 34¾ÈÀ» ´ë»óÀ¸·Î ÇÏ¿´À¸¸ç Áֻ縦 ½ÃÇàÇÑ ´«ÀÇ ¹Ý´ë¾È 24¾ÈÀ» ´ëÁ¶±ºÀ¸·Î ÇÏ¿´´Ù. ÁÖ»ç Àü, ÁÖ»ç ÈÄ 1°³¿ù ¹× 3°³¿ù¿¡ ºû°£¼·´ÜÃþÃÔ¿µÀ» ÀÌ¿ëÇÏ¿© Áß½ÉȲ¹ÝµÎ²² ¹× ¸Á¸· Ç÷°üÀÇ Á÷°æÀ» 0.5-1À¯µÎÁ÷°æ ¶³¾îÁø µ¿ÀÏÇÑ ÁöÁ¡¿¡¼ ÃøÁ¤ÇÏ¿´´Ù.
°á °ú: ¼Òµ¿¸ÆÀÇ Á÷°æÀº Ä¡·á 3°³¿ù ÈÄ¿¡ À¯ÀÇÇÏ°Ô °¨¼ÒÇÏ¿´´Ù(p=0.024). ¼ÒÁ¤¸ÆÀÇ Á÷°æÀº Ä¡·á 1°³¿ù ÈÄ(p=0.001), Ä¡·á 3°³¿ù ÈÄ ¸ðµÎ ÀÇ¹Ì ÀÖ°Ô °¨¼ÒµÈ °ªÀ» º¸¿´´Ù(p=0.000). Ä¡·á 3°³¿ù ÈÄ ¼ÒÁ¤¸Æ Á÷°æÀÇ °¨¼ÒÄ¡´Â Áß½ÉȲ¹ÝµÎ²²ÀÇ °¨¼ÒÄ¡¿Í À¯ÀÇÇÑ »ó°ü°ü°è¸¦ º¸¿´´Ù(R=0.487, p=0.003).
°á ·Ð: ¾È³» º£¹Ù½ÃÁÖ¸¿ ÁÖ»ç ÈÄ ¼Òµ¿¸Æ, ¼ÒÁ¤¸Æ ¸ðµÎ¿¡¼ Á÷°æÀÌ °¨¼ÒÇÏ¿´À¸¸ç, Ä¡·á 3°³¿ù ÈÄ ¼ÒÁ¤¸Æ Á÷°æÀÇ °¨¼ÒµÈ Á¤µµ´Â Áß½ÉȲ¹Ý µÎ²²ÀÇ °¨¼ÒÄ¡¿Í À¯ÀÇÇÑ »ó°ü°ü°è¸¦ º¸¿´´Ù.
Purpose: To investigate retinal vascular caliber changes with Spectral Domain OCT after intravitreal bevacizumab injection in diabetic macular edema patients
Methods: Thirty-four eyes of 29 diabetic macular edema patients who were intravitreously injected with bevacizumab (1.25 g/0.05 ml) were studied. Twenty-four fellow eyes of 24 patients with bevacizumab injection were also recruited as a control group. We measured retinal vascular caliber a distance of 0.5-1 disc sizes from the disc margin with Spectral Domain OCT at baseline and 1-month and 3-month follow-up visits. Central macular thicknesses were also measured.
Results: Over the 3 months of study, there was a significant reduction of arteriolar caliber compared to baseline (p = 0.024), There was significant reduction of venular caliber at 1 month (p = 0.001) and 3 months (p = 0.000) compared to baseline. Venular caliber reduction at the 3-month follow-up was significantly correlated with central macular thickness (R = 0.487, p = 0.003).
Conclusions: Retinal venular caliber reduction was significant at 1- and 3-month follow-up, and arteriolar caliber reduction was significant at 3-month follow-up compared to baseline. After 3 months of treatment, venular caliber reduction was correlated with reduction of central macular thickness.
Ű¿öµå
Central macular thickness; Retinal arteriolar caliber; Retinal venular caliber
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸